Lung cancer trials in China

In China 1143 Also abroad 2747

1,143 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Where
Guangzhou, Jinan, Shanghai
Age
18 years and over
People
914 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT06131840 · EU 2023-505858-18-00
Phase 1Taking people
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
Where
Chengdu
Age
18 years to 70 years
People
30
Run by
Sichuan University
See details and how to joinNCT06348797
Phase 2Taking people
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
Where
Cangzhou, Fu'zhou, Guangzhou, Harbin, Hefei, Nanning, Shanghai, Wuha, Xinxiang, Xuzhou
Age
18 years to 75 years
People
120
Run by
Shanghai Henlius Biotech
See details and how to joinNCT07253142
Phase 2Taking people
A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy
Where
Zhengzhou
Age
18 years to 75 years
People
200
Run by
Henan Cancer Hospital
See details and how to joinNCT07559786
No phaseNot yet taking people in China
JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC
Where
Hefei, Shanghai
Age
18 years to 75 years
People
20
Run by
Huan Zhou
See details and how to joinNCT07714304
Phase 2Not yet taking people in China
A Phase 2 Study of ABSK043 Combined With Osimertinib
Where
Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Taiyuan, Wuhan
Age
18 years and over
People
72
Run by
Abbisko Therapeutics Co, Ltd
See details and how to joinNCT07710612
No phaseTaking people
Clinical Study of a New Treatment Model for Elderly Lung Cancer Patients
Where
Beijing
Age
65 years and over
People
1,000
Run by
Peking University People's Hospital
See details and how to joinNCT07632664
Phase 2Not yet taking people in China
The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer
Where
Shanghai
Age
18 years to 70 years
People
180
Run by
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07704645
Phase 3Taking people
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Where
Anyang, Baoding, Beijing, Binzhou, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Guilin, Guiyang, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nanyang, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Ürümqi, Wenzhou, Wuhan, Wuhu, Xiamen, Xi'an, Xiangyang, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai, Zhuzhou
Age
18 years to 75 years
People
574
Run by
RemeGen Co., Ltd.
See details and how to joinNCT07416474
Phase 2Taking people
A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
Where
Guangzhou
Age
18 years to 75 years
People
348
Run by
Akeso
See details and how to joinNCT07669779
Early phase 1Taking people
Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer
Where
Wuhan
Age
18 years and over
People
36
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07689643
Phase 1Not yet taking people in China
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
Where
Shanghai
Age
18 years and over
People
258
Run by
Haisco Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07699757
Phase 1/2Taking people
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
Where
Hangzhou
Age
18 years to 75 years
People
116
Run by
Wuhan YZY Biopharma Co., Ltd.
See details and how to joinNCT05543330
No phaseTaking people
Primary Tumor Resection for M1a Stage Lung Cancer
Where
Shanghai
Age
18 years to 75 years
People
66
Run by
Fudan University
See details and how to joinNCT06547710
Phase 2Taking people
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
Where
Changsha
Age
18 years and over
People
15
Run by
Hunan Cancer Hospital
See details and how to joinNCT07314216
Phase 1Taking people
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC
Where
Beijing, Shanghai
Age
18 years to 75 years
People
138
Run by
Shanghai Henlius Biotech
See details and how to joinNCT07416695
No phaseTaking people
Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
Where
Changsha
Age
18 years and over
People
300
Run by
Central South University
See details and how to joinNCT06699979
Phase 2Taking people
JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
Where
Shanghai
Age
18 years to 75 years
People
35
Run by
Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT07518160
No phaseNot yet taking people in China
A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.
Where
Nanning
Age
18 years and over
People
500
Run by
First Affiliated Hospital of Guangxi Medical University
See details and how to joinNCT07686185
Phase 2Taking people
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
Where
Tianjin
Age
18 years to 75 years
People
25
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07358676
Phase 1/2Taking people
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
Where
Chengdu, Guangzhou, Harbin, Zhengzhou
Age
18 years and over
People
294 worldwide
Run by
Avistone Biotechnology Co., Ltd.
See details and how to joinNCT07538804
Phase 1Taking people
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
Where
Guangzhou
Age
18 years to 75 years
People
396
Run by
Hansoh BioMedical R&D Company
See details and how to joinNCT07645222
Phase 1Taking people
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Where
Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanchang, Shanghai, Shenyang, Wuhan
Age
18 years and over
People
214
Run by
Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT06839105
Phase 3Taking people
Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）
Where
Shanghai
Age
18 years to 75 years
People
380
Run by
CSPC Megalith Biopharmaceutical Co.,Ltd.
See details and how to joinNCT06927986
Phase 2Taking people
Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
Where
Guangzhou
Age
18 years to 75 years
People
160
Run by
Sun Yat-sen University
See details and how to joinNCT07609121